PharmaGap Files Provisional Patent Application for Liposomal Formulations of GAP-107B8

PharmaGap Inc. has announced that it has filed the second of two provisional patent applications with the United States Patent and Trademark Office ("USPTO") covering the results of development of PharmaGap's lead cancer drug GAP-107B8 during 2011 to date.

These two provisional patent filings covering the GAP-107B8 formulations represent significant steps forward in the Company's ability to realize value from the Company's drug development program.

This filing, titled "Liposomal Formulations of Cationic Peptides and Uses Thereof" addresses the liposome formulations developed by PharmaGap as well as these liposomal formulations carrying the original or modified versions of GAP-107B8.

Liposomes consist of one or more concentric lipid layers enclosing an internal aqueous volume and are unique in their ability to carry a variety of therapeutic compounds.

The specific lipids used in constructing the liposome can be selected to facilitate interaction with the drug cargo and/or with the target cell, making these systems extremely versatile drug delivery systems.

The successful development of these liposomal formulations of original and modified GAP-107B8 has significantly widened the GAP-107B8 Therapeutic Window (the range of doses between the lowest effective dose and the highest dose where unacceptable toxicity becomes evident), a key consideration for effective clinical trial design and ultimate success of the drug in the marketplace.